CULS Conversion and Additional Listing

RNS Number : 6785N

Alliance Pharma PLC

10 September 2013

 

For immediate release

10 September 2013

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

CULS Conversion and Additional Listing

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has received a conversion request in respect of £60,000 nominal value of the Company's 8% Convertible Unsecured Loan Stock.  Accordingly, the Company has allotted 285,714 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.

Application has been made by Alliance for the 285,714 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 16 September 2013.

Following conversion and allotment, Alliance will have 251,723,626 Ordinary Shares and £2,595,025 of 8% Convertible Unsecured Loan Stock in issue.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

MSCKMGMLVGGGFZM